Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy In Treatment For Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-Based Therapy

    Cancer Categories
    • Hematologic (Blood Cancers)
    Karmanos Trial ID
    • 2020-054
    NCT ID
    • NCT04140162
    Age Group
    • Adult
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase II
    Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
    • Phase II
    Principal Investigator
    • Andrew
      Kin, M.D.

      Oncology - Hematology, Oncology - Medical View Profile


    Primary Objective:
    • To determine the rate of MRD negativity after daratumumab-based induction and consolidation therapy if necessary in both transplant eligible and ineligible newly diagnosed MM patients.
    Secondary Objectives:
    • To describe the overall survival (OS) of patients who received daratumumab-based combination regimen.
    • To describe the progression free survival (PFS) of patients who received daratumumab-based combination regimen.
    • To describe the rate of MRD conversion after consolidation in patients who were MRD positive after initial induction.
    • To describe duration of sustained MRD negativity at time points of post-induction, post-consolidation, and post1year maintenance.
    • To determine the quality of life of patients enrolled on the study as reflected in patient reported outcomes.
    • To evaluate the safety and tolerability of daratumumab-based combination regimens in both transplant eligible and ineligible patient populations.
    • To estimate the proportion of patients with a successful stem cell mobilization after receiving daratumumab-based induction therapy.
  • Locations


    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Lawrence and Idell Weisberg Cancer Treatment Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266